Key facts
- It has raised $6.8M; the latest was Seed Round ($6.8M) in Jan 2025.
- Notable investors include Kindstar Global, Rivercity Investment.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Tuoruijing
- ·The full record, as it builds
Funding rounds
No funding rounds for Tuoruijing are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tuoruijing
Developer of super multiplex diagnostic technology platform focusing on Point-of-Care Testing (POCT) technology. The company's detection equipment can complete the detection of up to thousands of targets in a short time and issue reports, providing clients with faster detection speed and customized reaction cartridges.
- Sector
- Healthcare
- HQ
- Wuhan, China
- Founded
- 2024
- Ownership
- Privately Held (backing)
Tuoruijing doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tuoruijing shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tuoruijing in its N-PORT filings yet. We sweep new filings monthly.